• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by OptiNose Inc.

    2/13/25 12:38:02 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OPTN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    OptiNose, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    68404V209

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    68404V209


    1Names of Reporting Persons

    Stonepine Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    588,657.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    588,657.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    588,657.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.9 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  Percentage calculated based on 10,055,300 shares of Common Stock outstanding following the 1-for-15 reverse split of the Issuer's Common Stock on December 30, 2024, as reported in the Form 8-K filed by the Issuer on December 30, 2024.


    SCHEDULE 13G

    CUSIP No.
    68404V209


    1Names of Reporting Persons

    Stonepine Capital, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    588,657.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    588,657.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    588,657.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.9 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Percentage calculated based on 10,055,300 shares of Common Stock outstanding following the 1-for-15 reverse split of the Issuer's Common Stock on December 30, 2024, as reported in the Form 8-K filed by the Issuer on December 30, 2024.


    SCHEDULE 13G

    CUSIP No.
    68404V209


    1Names of Reporting Persons

    Stonepine GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    588,657.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    588,657.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    588,657.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.9 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Percentage calculated based on 10,055,300 shares of Common Stock outstanding following the 1-for-15 reverse split of the Issuer's Common Stock on December 30, 2024, as reported in the Form 8-K filed by the Issuer on December 30, 2024.


    SCHEDULE 13G

    CUSIP No.
    68404V209


    1Names of Reporting Persons

    Jon M. Plexico
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    588,657.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    588,657.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    588,657.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.9 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  Percentage calculated based on 10,055,300 shares of Common Stock outstanding following the 1-for-15 reverse split of the Issuer's Common Stock on December 30, 2024, as reported in the Form 8-K filed by the Issuer on December 30, 2024.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    OptiNose, Inc.
    (b)Address of issuer's principal executive offices:

    777 Township Line Road, Suite 300, Yardley, PA 19067
    Item 2. 
    (a)Name of person filing:

    Stonepine Capital Management, LLC, a Delaware limited liability company ("Stonepine") Stonepine Capital, L.P., a Delaware limited partnership (the "Partnership") Stonepine GP, LLC, a Delaware limited liability company (the "General Partner") Jon M. Plexico Stonepine and the General Partner are the investment adviser and general partner, respectively, of the Partnership. Mr. Plexico is the control person of Stonepine and the General Partner. The reporting persons are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Common Stock covered by this Schedule 13G.
    (b)Address or principal business office or, if none, residence:

    919 NW Bond Street, Suite 204 Bend, OR 97703
    (c)Citizenship:

    See Item 4 of the cover sheet for each reporting person.
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    68404V209
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Stonepine: 588,657 Partnership: 588,657 General Partner: 588,657 Jon M. Plexico: 588,657
    (b)Percent of class:

    Stonepine: 5.9% Partnership: 5.9% General Partner: 5.9% Jon M. Plexico: 5.9%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Stonepine: 0 Partnership: 0 General Partner: 0 Jon M. Plexico: 0

     (ii) Shared power to vote or to direct the vote:

    Stonepine: 588,657 Partnership: 588,657 General Partner: 588,657 Jon M. Plexico: 588,657

     (iii) Sole power to dispose or to direct the disposition of:

    Stonepine: 0 Partnership: 0 General Partner: 0 Jon M. Plexico: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Stonepine: 588,657 Partnership: 588,657 General Partner: 588,657 Jon M. Plexico: 588,657

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Partnership holds Common Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Stonepine Capital Management, LLC
     
    Signature:/s/ Jon M. Plexico
    Name/Title:Managing Member
    Date:02/13/2025
     
    Stonepine Capital, L.P.
     
    Signature:/s/ Jon M. Plexico
    Name/Title:Managing Member of the General Partner, Stonepine GP, LLC
    Date:02/13/2025
     
    Stonepine GP, LLC
     
    Signature:/s/ Jon M. Plexico
    Name/Title:Managing Member
    Date:02/13/2025
     
    Jon M. Plexico
     
    Signature:/s/ Jon M. Plexico
    Name/Title:Reporting person
    Date:02/13/2025
    Get the next $OPTN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OPTN

    DatePrice TargetRatingAnalyst
    3/20/2025Buy → Hold
    Lake Street
    1/3/2025$5.00 → $18.00Buy
    H.C. Wainwright
    3/11/2024$5.00Buy
    H.C. Wainwright
    8/21/2023$3.00Buy
    Lake Street
    10/21/2022$5.00Buy
    Jefferies
    More analyst ratings

    $OPTN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    OptiNose downgraded by Lake Street

    Lake Street downgraded OptiNose from Buy to Hold

    3/20/25 8:56:55 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright reiterated coverage on OptiNose with a new price target

    H.C. Wainwright reiterated coverage of OptiNose with a rating of Buy and set a new price target of $18.00 from $5.00 previously

    1/3/25 7:58:58 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on OptiNose with a new price target

    H.C. Wainwright initiated coverage of OptiNose with a rating of Buy and set a new price target of $5.00

    3/11/24 7:44:36 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPTN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer & Corp Sec Marino Michael F Iii returned 125,204 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - OptiNose, Inc. (0001494650) (Issuer)

    5/21/25 9:26:54 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Kohler Terry returned 30,541 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - OptiNose, Inc. (0001494650) (Issuer)

    5/21/25 9:26:25 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Fletcher R John

    4 - OptiNose, Inc. (0001494650) (Issuer)

    5/21/25 9:26:21 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPTN
    SEC Filings

    View All

    SEC Form 15-12G filed by OptiNose Inc.

    15-12G - OptiNose, Inc. (0001494650) (Filer)

    6/2/25 1:57:42 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by OptiNose Inc.

    EFFECT - OptiNose, Inc. (0001494650) (Filer)

    5/22/25 12:15:04 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by OptiNose Inc.

    EFFECT - OptiNose, Inc. (0001494650) (Filer)

    5/22/25 12:15:09 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPTN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

    BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists and community care providers, that address important medical and public health threats, today announced that the Company has completed its acquisition of Optinose, Inc. (NASDAQ:OPTN). This acquisition broadens Paratek's commercial portfolio which now includes both its flagship antibiotic, NUZYRA® (omadacycline), and Optinose's product XHANCE® (fluticasone propionate). "Adding XHANCE to our portfolio is a pivotal first step in achieving our long-term vision to become a multi‑product specialty

    5/21/25 8:26:34 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

    Company reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to prior year periods Company reports 23% prescription growth from third quarter 2024 to fourth quarter 2024 YARDLEY, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2024, and provided recent operational highlights. Fourth Quarter 2024 and Recent Highlights New Prescriptions (NRx) and Total Prescriptions (TRx)An inflection in prescription demand first

    3/26/25 7:00:00 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

    YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time. The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other customary closing conditions. The Company now expects to report results for the three- and twelve-month periods ended D

    3/19/25 9:45:38 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPTN
    Financials

    Live finance-specific insights

    View All

    Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

    BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists and community care providers, that address important medical and public health threats, today announced that the Company has completed its acquisition of Optinose, Inc. (NASDAQ:OPTN). This acquisition broadens Paratek's commercial portfolio which now includes both its flagship antibiotic, NUZYRA® (omadacycline), and Optinose's product XHANCE® (fluticasone propionate). "Adding XHANCE to our portfolio is a pivotal first step in achieving our long-term vision to become a multi‑product specialty

    5/21/25 8:26:34 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

    YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time. The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other customary closing conditions. The Company now expects to report results for the three- and twelve-month periods ended D

    3/19/25 9:45:38 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)

    Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10‑million‑patient marketAcquisition advances Paratek's vision to become a multi-product company focused on innovative specialty therapies Total transaction value of up to ~$330 million Potential consideration of up to $14 per share, including upfront consideration of $9 per share, representing a 50% premium to Optinose's closing trading price on March 19, 2025 BOSTON and YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ:OPTN) today announced they have entered into a definitive merger agreement under w

    3/19/25 9:25:02 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPTN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by OptiNose Inc.

    SC 13G - OptiNose, Inc. (0001494650) (Subject)

    11/20/24 5:21:26 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by OptiNose Inc.

    SC 13G/A - OptiNose, Inc. (0001494650) (Subject)

    11/14/24 4:54:20 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by OptiNose Inc.

    SC 13G/A - OptiNose, Inc. (0001494650) (Subject)

    11/12/24 10:32:10 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPTN
    Leadership Updates

    Live Leadership Updates

    View All

    Optinose Appoints Terry Kohler as Chief Financial Officer

    YARDLEY, Pa., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Terry Kohler as Chief Financial Officer. Mr. Kohler was most recently the Chief Financial Officer for Verrica Pharmaceuticals, a dermatology therapeutics company, where he supported commercial preparations for the launch of a topical treatment for molluscum contagiosum and research and development pipeline investments. Mr. Kohler is an experienced biotech finance leader with over 20 years of business experience. "We are pleased to add Terry to our leadership team to help guide

    10/7/24 4:59:53 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Optinose Announces CEO Transition and Business Update

    YARDLEY, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Peter Miller has stepped down as Chief Executive Officer and Board member, and that Ramy Mahmoud, MD, MPH has been appointed as Chief Executive Officer and Board member. In announcing his departure, Peter Miller shared, "It has been a privilege working with the amazing group of colleagues at Optinose. I am proud of all that we have accomplished and the impact we continue to make in our mission to improve patients' lives." During Mr. Miller's nearly 13 years as CEO, the Company experienced s

    1/31/23 7:00:00 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Optinose Appoints Paul Spence as Chief Commercial Officer

    YARDLEY, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Paul Spence as Chief Commercial Officer. Mr. Spence was most recently the Senior Vice President of the U.S. Commercial Organization at Nestlé Health Sciences where he built the commercial capabilities for the Aimmune Gastrointestinal and Food Allergy businesses. Mr. Spence has 30 years of experience in the life science and pharmaceuticals industry as a leader responsible for marketing, sales, market access, operations, and supply chain. Prior to joining Nestlé Health Sciences,

    12/15/22 4:30:00 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care